RxDoctor Payments Data

Kurt Johnson, MD

Family Medicine · Pearl, MSNPI 1598754913

Payments from drug & device makers

$6,382in general payments, 2019–2025

Across 360 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$979
  • AstraZeneca$943
  • AbbVie$764
  • Novo Nordisk$649
  • Abbott$367
  • Pfizer$315
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$6,25298%
  • Education$1292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,382 in reported general payments places this provider in the 85th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$131,427
Medicare patients
288
Services billed
2,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide96$108,230
JardianceEmpagliflozin101$100,827
OzempicSemaglutide69$99,019
EliquisApixaban94$78,393
FarxigaDapagliflozin Propanediol45$45,211
JanuviaSitagliptin Phosphate29$35,568
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$27,561
EntrestoSacubitril/Valsartan20$18,884
MyrbetriqMirabegron19$18,488
LinzessLinaclotide18$18,317
XareltoRivaroxaban19$15,984
MounjaroTirzepatide15$15,607
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$12,992
TrulicityDulaglutide13$12,506
VascepaIcosapent Ethyl11$9,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$649$207,248165 claims
Boehringer IngelheimJardiance, Stiolto Respimat$282$107,968117 claims
PfizerEliquis, Premarin$315$82,063110 claims
AstraZenecaFarxiga$943$45,21145 claims
MerckJanuvia$296$35,56829 claims
GSKTrelegy Ellipta, Incruse Ellipta$979$30,90956 claims
Lilly USA, LLCMounjaro, Trulicity$244$28,11328 claims
AbbVieLinzess, Synthroid$764$21,50960 claims
NovartisEntresto$49$18,88420 claims
Astellas Pharma US IncMyrbetriq$130$18,48819 claims
Johnson & JohnsonXarelto$44$15,98419 claims
Scilex Pharmaceuticals Inc.Colchicine$14$3,60849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Pearl

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →